Skip to content
PubMed This is a summary of 80 peer-reviewed journal articles Updated
Cardiology

Naxos disease: A Patient Guide

At a Glance

Naxos disease is an inherited condition marked by woolly hair and thickened skin on the palms and soles, followed by a risk of heart muscle disease. Early cardiology follow-up, exercise limits, and family screening can help detect and manage heart involvement.

Naxos disease is a rare, inherited condition that acts as a bridge between the health of the skin and the strength of the heart. It is part of a group of conditions known as cardiocutaneous syndromes, where visible signs on the outside of the body provide critical clues about how the heart is functioning [1][2]. While a diagnosis can be daunting, the unique way Naxos disease progresses offers an opportunity to initiate cardiac surveillance before heart symptoms begin, though it does not guarantee the prevention of future issues [3][4].

This condition is defined by a specific “triad” of features that often appear in a sequence, though they are not always all present at the time of assessment. First, children are often born with or soon develop woolly hair, which is unusually tightly curled and sometimes fragile [1]. This is followed by palmoplantar keratoderma, a thickening of the skin on the palms of the hands and the soles of the feet that usually becomes noticeable as a child begins to crawl and walk [5]. The final part of the triad is arrhythmogenic cardiomyopathy, a heart condition where the muscle is gradually replaced by fibrous scar tissue and fat [2]. This structural change can interfere with the heart’s electrical system, potentially leading to irregular rhythms or a weakened pump over time [6].

The progression of Naxos disease is often age-dependent, meaning it changes as you grow. While the hair and skin features are usually present in early childhood, heart involvement typically does not become clinically apparent until adolescence or young adulthood [1][7]. Because the hair and skin signs are visible so early, they serve as a prompt for doctors to begin heart monitoring long before a teenager might experience palpitations, dizziness, or fainting [3][8]. This early window is the best time to build a specialized care team, including a cardiologist, dermatologist, and geneticist, to create a proactive plan for the years ahead [4].

Living with Naxos disease requires a focus on preservation and prevention. One of the most critical elements of management is exercise restriction. High-intensity, competitive, or endurance sports put immense mechanical strain on the heart muscle, which can trigger dangerous arrhythmias and accelerate the progression of the disease [9][10]. While low-intensity activity is often safe and encouraged, avoiding heavy exertion is a cornerstone of protecting heart function for those affected [11][12]. Alongside activity limits, management includes lifelong heart monitoring tailored to the individual’s risk, as well as medications like beta-blockers to help manage documented arrhythmias or symptoms [13][3].

Because Naxos disease is an autosomal recessive condition—meaning a person typically inherits one mutated gene from each parent—family health is also a priority. Siblings of a person with Naxos disease have a 25% chance of being affected (two mutated copies), a 50% chance of being a carrier (one mutated copy), and a 25% chance of inheriting neither [6]. Doctors recommend cascade screening, which involves genetic testing and clinical heart evaluations for brothers and sisters, even if they do not yet show any signs of the condition [14][15]. By identifying and monitoring affected family members early, you can implement protective strategies that prioritize long-term heart health and overall well-being [5][16].

Common questions in this guide

What are the main signs of Naxos disease?
The classic pattern includes woolly, tightly curled hair; thickened skin on the palms and soles; and arrhythmogenic cardiomyopathy, in which heart muscle is replaced by scar tissue and fat. Hair and skin changes often appear in childhood, while heart involvement may not become evident until adolescence or young adulthood.
Why does a child with Naxos disease need heart checks if they feel well?
Heart involvement can develop after the hair and skin signs and may be present before palpitations, dizziness, or fainting. Regular ECGs, echocardiograms, and sometimes cardiac MRI help the care team look for electrical or structural changes and set follow-up based on individual risk.
What activities should someone with Naxos disease avoid?
High-intensity, competitive, endurance, and heavy-exertion activities can strain the heart and may increase the risk of dangerous rhythms or disease progression. Low-intensity activity may be allowed, but the treating cardiologist should define what is safe for the individual.
How is Naxos disease inherited, and what are the chances for siblings?
Naxos disease is usually autosomal recessive, so an affected person inherits one altered copy of the relevant gene from each parent. For each sibling, the chance is 25% of being affected, 50% of being a carrier, and 25% of inheriting neither altered copy.
What treatment and long-term care does Naxos disease involve?
Care usually includes lifelong heart monitoring, avoiding high-risk exercise, and follow-up with cardiology, dermatology, and medical genetics. Beta-blockers may be prescribed when documented arrhythmias or symptoms require them; treatment is tailored to the person's findings and risk.

Get notified when new evidence is published on Naxos disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Naxos Disease and Related Cardio-Cutaneous Syndromes.

    Protonotarios A, Asimaki A, Basso C, et al.

    JACC. Advances 2025; (4(2)):101547 doi:10.1016/j.jacadv.2024.101547.

    PMID: 39877668
  2. 2

    Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy.

    Islam AM, Rahman MT, Chowdhury AH

    Cardiovascular diagnosis and therapy 2016; (6(5)):462-465 doi:10.21037/cdt.2016.03.07.

    PMID: 27747171
  3. 3

    Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.

    Protonotarios I, Alsergani H, Anastasakis A, et al.

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.

    PMID: 41936932
  4. 4

    Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases.

    Polivka L, Bodemer C, Hadj-Rabia S

    Journal of medical genetics 2016; (53(5)):289-95 doi:10.1136/jmedgenet-2015-103403.

    PMID: 26399581
  5. 5

    Naxos disease: current insights from early clinical observations to genetics and precision medicine.

    Xylouri Z, Al-Sergani H, Protonotarios I, et al.

    Internal and emergency medicine 2026; doi:10.1007/s11739-026-04559-9.

    PMID: 42932075
  6. 6

    Naxos disease - a narrative review.

    Leopoulou M, Mattsson G, LeQuang JA, et al.

    Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.

    PMID: 32966140
  7. 7

    Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility.

    Vahidnezhad H, Youssefian L, Faghankhani M, et al.

    Scientific reports 2020; (10(1)):21622 doi:10.1038/s41598-020-78344-9.

    PMID: 33303784
  8. 8

    Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy.

    Pigors M, Schwieger-Briel A, Cosgarea R, et al.

    Acta dermato-venereologica 2015; (95(3)):337-40 doi:10.2340/00015555-1974.

    PMID: 25227139
  9. 9

    Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy.

    Lie ØH, Dejgaard LA, Saberniak J, et al.

    JACC. Clinical electrophysiology 2018; (4(6)):744-753 doi:10.1016/j.jacep.2018.01.010.

    PMID: 29929667
  10. 10

    Physical Activity in Arrhythmogenic Cardiomyopathy: From Trigger to Therapeutic Dilemma.

    Kayvanpour E, Meder B, Sedaghat-Hamedani F

    Reviews in cardiovascular medicine 2026; (27(8)):52871 doi:10.31083/RCM52871.

    PMID: 42694556
  11. 11

    Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC/ALVC or Both?

    Bennett RG, Haqqani HM, Berruezo A, et al.

    Heart, lung & circulation 2019; (28(1)):164-177 doi:10.1016/j.hlc.2018.10.013.

    PMID: 30446243
  12. 12

    Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.

    Gasperetti A, James CA, Cerrone M, et al.

    European heart journal 2021; (42(13)):1231-1243 doi:10.1093/eurheartj/ehaa821.

    PMID: 33200174
  13. 13

    Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

    Akdis D, Brunckhorst C, Duru F, Saguner AM

    Arrhythmia & electrophysiology review 2016; (5(2)):90-101 doi:10.15420/AER.2016.4.3.

    PMID: 27617087
  14. 14

    Genotype and cardiac outcome in patients with cardiocutaneous syndrome (Naxos disease variant: Carvajal syndrome).

    Binfadel M, Aleem MU, Alhabdan M, et al.

    Orphanet journal of rare diseases 2025; (20(1)):137 doi:10.1186/s13023-025-03612-8.

    PMID: 40108711
  15. 15

    [Genetic diagnostics for cardiomyopathies].

    Czepluch F, Wollnik B, Hasenfuß G

    Deutsche medizinische Wochenschrift (1946) 2017; (142(9)):657-664 doi:10.1055/s-0042-112183.

    PMID: 28454199
  16. 16

    Clinical and Molecular Aspects of Naxos Disease.

    Protonotarios I, Asimaki A, Xylouri Z, et al.

    Heart failure clinics 2022; (18(1)):89-99 doi:10.1016/j.hfc.2021.07.010.

    PMID: 34776086

This page is for informational purposes only and does not constitute medical advice about Naxos disease. Your cardiologist, dermatologist, and geneticist should guide decisions about heart testing, activity, family screening, and treatment.